Dr. Schatz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1475 NW 12th Ave
Fl 1
Miami, FL 33136Phone+1 305-243-1000Fax+1 305-243-8470- Is this information wrong?
Summary
- Dr. Jonathan Schatz is a physician-scientist in Miami, FL at University of Miami Hospital and University of Miami Hospital and Clinics. He received his medical degree from University of Chicago Division of the Biological Sciences The Pritzker School of Medicine and has been in practice 13 years. He trained in hematology-oncology at Memorial Sloan-Kettering Cancer Center. He specializes in hematologic oncology and is experienced in Hodgkin and non-Hodgkin lymphomas. He has more than 50 publications and over 2,500 citings.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
- University of ChicagoResidency, Internal Medicine, 2004 - 2007
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2004
Certifications & Licensure
- FL State Medical License 2015 - 2025
- AZ State Medical License 2012 - 2015
- NY State Medical License 2007 - 2012
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Mortimer J. Lacher Fellowship Memorial Sloan-Kettering Cancer Center, 2009
- First Place, Resident Poster Competition American College of Physicians, Northern Illinois Chapter Scientific Meeting, 2005
- Leon O. Jacobson Prize University of Chicago Pritzker School of Medicine, 2004
- Join now to see all
Publications & Presentations
PubMed
- Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.Arumov, A., Trabolsi, A., Schatz, J.> ;Blood Cancer Journal. 2024 Feb 8
- Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma.Austin D Newsam, Caroline A Coughlin, Asaad Trabolsi, Jonathan H Schatz> ;Leukemia & Lymphoma. 2023 Dec 1
- 5 citationsEfficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G Karrison, Rachel Treitman, Manali K Kamdar, Bradley M Haverkos, James Godfrey, Melissa A Babcook, Timothy J V...> ;Blood Advances. 2023 Aug 22
- Join now to see all
Journal Articles
- Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer CellsAmin AD, Rajan SS, Groysman MJ, Pongtornpipat P, Schatz JH, Biomarkers in Cancer, 1/15/2015
- Kinase overexpressing cancers responsive to drug withdrawalAmin AD, Rajan SS, Schatz JH, Aging, 1/1/2015
- Evidence suggesting that discontinuous dosing of ALK kinase inhibitors may prolong control of ALK+ tumorsAmin AD, Rajan SS, Lang WS, Pongtornpipat P, Groysman MJ, Tapia EO, Tula-Sanchez AA, Peters TL, Cuyugan L, Adkins J, Rimsza LM, Lussier YA, Puvvada SD, Schatz JH, Cancer Research, 1/1/2015
- Join now to see all
Abstracts/Posters
- Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell LymphomaJonathan H. Schatz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint R...Jonathan H. Schatz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma TherapeuticsJonathan H. Schatz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Discovery and Early Characterization of a New Inhibitor of Cap-Dependent Translation for Cancer Therapy.University of Miami - 1/1/2016
- The China Lymphoma Project: A Medical Perspective.1/1/2016
- Studies of Preclinical Therapeutics and Resistance in Lymphoma Model Systems.University of Arizona - 1/1/2015
- Join now to see all
Press Mentions
- Castaways Against Cancer Announces Five-Year Commitment to Sylvester Comprehensive Cancer CenterMarch 15th, 2022
- Bispecific Antibodies Treat Cancer in Mouse ModelsMarch 5th, 2021
Hospital Affiliations
- University of Miami HospitalMiami, Florida
- UMHC-Sylvester Comprehensive Cancer CenterMiami, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: